drugset / Trial / NCT00122668

Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients

NCT00122668

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this randomized study is to compare the occurrence of lipoatrophy in HIV-1 infected, naive patients receiving either a nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor (NNRTI) and boosted protease inhibitor (PI), or a standard antiretroviral therapy with 2 NRTI plus either PI or NNRTI. Lipoatrophy is evaluated by measurement of fat volume by computed tomography (CT)-scan and DEXA (Dual Energy X-ray Absorptiometry).

Timeline

Start
2003-11
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified
Subject INDINAVIR ANHYDROUS Other / unclassified
Subject Lamivudine Other / unclassified
Subject Lopinavir Other / unclassified
Subject Nevirapine Small molecule
Subject Zidovudine Small molecule